Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Academia and the company coin

Nature Biotechnology volume 27, pages 411–414 (2009)Cite this article

An Erratum to this article was published on 01 July 2009

This article has been updated

As the economic downturn chokes spin-outs from academia, a spate of newly minted university-industry partnerships are springing up. Failing to address the financial conflicts in such partnerships could spell trouble for both faculty and drug companies. Jim Kling investigates.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Students give most universities a failing grade.

Change history

  • 08 July 2009

    In the version of this article initially published, on p. 411, left column, last paragraph, one of the researchers’ names was incorrectly given as “Martin Feller.” It should have read Martin Keller. The error has been corrected in the HTML and PDF versions of the article.

References

  1. Wilson, D. Harvard Medical School in ethics quandary. The New York Times <http://www.nytimes.com/2009/03/03/business/03medschool.html?em> 2 March 2009, B1.

    Google Scholar 

  2. Kowalczyk, L. US cites Boston psychiatrist in case vs. drug firm. The Boston Globe <http://www.boston.com/news/education/higher/articles/2009/03/06/us_cites_boston_psychiatrist_in_case_vs_drug_firm/> 6 March 2009.

    Google Scholar 

  3. Kowalczyk, L. State bans drug firm gifts to doctors. Boston Globe <http://www.boston.com/news/local/massachusetts/articles/2009/03/12/state_bans_drug_firm_gifts_to_doctors/?page=full 12 March 2009.

    Google Scholar 

  4. Harris, G. & Carey, B. Researchers fail to reveal full drug pay. The New York Times 8 June 2008, A1.

    Google Scholar 

  5. Dana, J. & Loewenstein, G. J. Am. Med. Assoc. 290, 252–255 (2003).

    Article  Google Scholar 

  6. Steinman, M.A., Shlipak, M.G. & McPhee, S.J. Am. J. Med. 110, 551–557 (2001).

    Article  CAS  Google Scholar 

  7. Turner, E.H. et al. New Engl. J. Med. 358, 252–260 (2008)

    Article  CAS  Google Scholar 

  8. Wazana, A. J. Am. Med. Assoc. 283, 373–380 (2000).

    Article  CAS  Google Scholar 

  9. Miller, F.G. & Brody, H. Academic Med. 80, 899–904 (2005).

    Article  Google Scholar 

  10. Ehringhaus, S. H, et al. J. Am. Med. Assoc. 299, 665–671 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bellingham, Washington

    Jim Kling

Authors
  1. Jim Kling
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kling, J. Academia and the company coin. Nat Biotechnol 27, 411–414 (2009). https://doi.org/10.1038/nbt0509-411

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0509-411

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing